It turns out Dr. Tony Fauci does indeed know Luc.
"I can't remember his last name, but do you know Luc of GSK?" Steve Clemons of The Atlantic asked the NIH's chief infectious disease guy...
...Slight disagreement about the state of vaccine development in the U.S...
(There are nearly 100,000 employees at the pharmaceutical giant, including 42,000 in Europe alone. I don’t know if this means the odds were not in anyone’s favor that Dr. Fauci would know Luc, or if it’s more likely he would know five Lucs, a dozen or so Lukes and probably some Lucases.)
This conversation between Dr. Fauci and Clemons, The Atlantic’s Washington editor-at-large, took place during the Washington Ideas policy forum, which popped up last week inside Rosa Mexicano. (Clemons responded to my tweet later that he was talking about this guy.)
Amid a bright pink backdrop, equally bright sangria (none for me!) and that famous guac (this was much harder to resist, but I managed), everyone from Madeleine Albright to the founder of &Pizza shared the same stage. Dr. Fauci, who is the director of the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, was up last week as part of the health and science track. He answered questions from Clemons on NIH funding, the AIDS epidemic, and, of course, Zika.
So I followed up with the NIAID the next day on the status of the phase II clinical trial for an experimental Zika vaccine (They announced that trial in March, and, hey, things can change…). And when the phone rang there was a distinctly Brooklyn voice on the other line.
"Hi Dr. Fauci. By the way, I figured out who Luc is."
"Luc Debruyne, president of global vaccines."
"Oh yeah! I know Luc."
And there you go. If you would like substantive information, such as the actual status of the Zika vaccine trial, that’s all in my article.
I also asked him about the status of the universal flu vaccine, but you’re going to have to subscribe to read that one...
Stay on top of new developments in health law and regulation with a free trial to the Health Law Resource Center.
Learn more about Bloomberg Law and sign up for a free trial.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)